Data presented at Psych Congress 2024 showed improvements in social functioning and quality of life over an eight-week ...

Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...

Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

Some people who took a new schizophrenia drug for a year improved with only a ... noting that fewer or milder side effects ...

044). Conversely, 6 taxa, such as rhodospirillaceae, defluviitaleaceae, and desulfovibrio, were protective against schizophrenia (OR: 0.88-0.94; P ≤.049). The findings may provide evidence for the ...

For the past 70 years, schizophrenia treatments all targeted the same chemical: dopamine. While that works for some, it ...

Art therapy can help individuals express thoughts and feelings without relying solely on words, providing a valuable outlet ...

Schizophrenia significantly shortens life expectancy by an estimated 15 years with excess mortality arising from multiple ...

Lyu X, Li Z, Chen S, et al. Transcranial direct current stimulation improves tardive dyskinesia in long-term hospitalized patients with chronic schizophrenia. Clin Neurophysiol. 2024;166:20-30. doi:10 ...

There are a few unmet needs in schizophrenia that can make a big difference in the prognosis and quality of life of patients.

It is very important to understand the symptoms of paranoid schizophrenia as early as possible to get the right treatment. Read on to learn more about this condition, why it happens, its symptoms and ...